AstraZeneca adds to obesity drug race, but Eli Lilly remains in lead
Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). On Thursday, AstraZeneca said it paid $185 million …